about
Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal ResultsRegulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo.Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.5-Fluorouracil derivatives: a patent review.Cumulative live birth rate after two single frozen embryo transfers (eSFET) versus a double frozen embryo transfer (DFET) with cleavage stage embryos: a retrospective cohort study.MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cellsTransdifferentiation: why and how?Nanomedicine: application areas and development prospects.New gene therapy strategies for cancer treatment: a review of recent patents.How is gene transfection able to improve current chemotherapy? The role of combined therapy in cancer treatment.Antitumor properties of natural compounds and related molecules.Cancer stem cells and their implication in breast cancer.Exosomes Derived from Breast Cancer Cells, Small Trojan Horses?Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells.Anticancer activity and cDNA microarray studies of a (RS)-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine, and an acyclic (RS)-O,N-acetalic 6-chloro-7H-purine.New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine.Differentiation of intestinal epithelial cells mediated by cell confluence and/or exogenous nucleoside supplementation.Tumour malignancy loss and cell differentiation are associated with induction of gef gene in human melanoma cells.Anticancer activity of (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: Preliminary cDNA microarray studies.A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells.Randomised clinical trial comparing elective single-embryo transfer followed by single-embryo cryotransfer versus double embryo transfer.Promotion of human adipose-derived stem cell proliferation mediated by exogenous nucleosides.Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.Antiproliferative Activity of Natural Taiwaniaquinoids and Related Compounds.The Role of Exosomes on Colorectal Cancer: a Review.First enantiospecific syntheses of marine merosesquiterpenes neopetrosiquinones a and B: evaluation of biological activity.Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance.Ultrastructural and molecular analyzes of insulin-producing cells induced from human hepatoma cellsSynthesis and antiproliferative activity of podocarpane and totarane derivatives
P50
Q26774897-B2393112-371F-41EF-9FCE-F628DF0C6996Q27692619-0A6CE68D-2D8A-4553-8B24-46DF3DADA28DQ30794332-55B47ABE-8251-4899-AAEA-C2E62E2211B7Q31134354-E0AB14DF-3B9A-4EED-8035-40485B9BCC50Q34253978-028F1103-5C17-4BEA-9E53-D51AC32C8397Q34603935-7E525BE8-FAAE-4887-88AF-817350421B7AQ36552798-E15F5856-5A20-4E98-887F-1A5F6C2ACDAAQ37279627-0F93969A-96C2-4777-A9EC-94B7E62429ECQ37854079-9CD86629-43DE-4253-9B96-2801AF08E02DQ37891690-F050FE09-C8CA-43F7-83E4-DBE87A3C70DFQ37984544-531347C4-064C-4C87-B299-9B8214473042Q37993177-3C2CAF3E-0057-40EF-B0B1-1EE97A2AD4DCQ38060199-F75F4A33-0EA1-46C6-A23D-51700675FE95Q38207159-22A56CA2-267F-4B3A-AE1C-DD4A5C1A471CQ38541161-1BDAC67D-49E3-4E4C-B537-65D642CB0CB0Q39514341-2C6D2B0A-BC70-41CD-BA89-6375D763C370Q39522330-DFB9D771-7DB8-4871-86D3-C8B61B552B5DQ39624625-7F9ABF56-50A6-485D-9037-8C487DC43BC0Q39749711-4816EFD1-C0B5-42AA-AFB5-DB7A95FC6260Q39970715-4BA6B8DF-76B1-4662-A819-CAF7C3239C62Q40025212-AD52AF00-D098-4F86-B971-F660CCADD3CBQ40204808-1C616297-68A8-4967-B551-6D948216066DQ41602758-D06A0766-73C5-41CF-935C-7F92B5B8A5A6Q43045214-3906089B-0AD6-40F7-A1DA-2A1D08B332ACQ45880297-1AA09716-3B45-45FE-9D78-9FEDC3AA61D3Q46896454-E340D542-A789-4C23-A7A8-26B8DFAA5F35Q47383855-95E5A0F0-28E5-42D3-A422-C59E9842EABAQ51359611-EDE6F754-9ECD-4F06-B90C-B37A4DC8B429Q54282316-DB58756E-3E94-42A5-82F8-163C0173E54BQ84598275-CC43022B-11DB-477F-83D1-33A4CE68FE1CQ91692024-FEDADABE-96EE-4BF0-AF62-E3F62565950C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Fernando Rodríguez-Serrano
@en
Fernando Rodríguez-Serrano
@nl
type
label
Fernando Rodríguez-Serrano
@en
Fernando Rodríguez-Serrano
@nl
prefLabel
Fernando Rodríguez-Serrano
@en
Fernando Rodríguez-Serrano
@nl
P31
P496
0000-0002-7105-4060